Ligand Pharmaceuticals

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in Emeryville, CA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Ligand Pharmaceuticals reports stellar Q4 earnings and growth prospects

Ligand Pharmaceuticals demonstrated robust financial performance in Q4 2022, driven by strong royalty revenue growth and strategic initiatives.
While facing challenges in cost optimization and label expectations, Ligand's focus on operational efficiency and growth opportunities positions it well for the future.
With a solid financial foundation, a diverse portfolio of assets, and a commitment to strategic growth, Ligand is poised for continued success and value creation.

Ligand Pharmaceuticals excels in Q1, eyes growth through strategic assets

Ligand Pharmaceuticals delivered robust Q1 results, positioning itself for continued growth and financial stability.
The company's strategic focus on high-quality assets, diversification, and efficient deal execution underscores its commitment to driving value for investors.
Despite market challenges, Ligand remains optimistic, leveraging opportunities in the biopharmaceutical sector to sustain growth and enhance shareholder value.

Ligand Pharmaceuticals excels in Q2, eyes strategic growth opportunities

Ligand Pharmaceuticals delivered a robust performance in Q2 2023, driven by strong revenue growth and strategic financial moves.
While facing challenges in contract revenue and competitive markets, Ligand's focus on key products and acquisitions signals resilience and adaptability.
Opportunities lie in expanding revenue streams, navigating market dynamics, and leveraging FDA developments for future growth.

Ligand Pharmaceuticals reports robust Q3 earnings and strategic investments

Ligand Pharmaceuticals showcased strong financial performance, strategic investments in late-stage products, and a focus on revenue growth and portfolio management. Despite challenges in clinical trials and market estimations, the company's emphasis on growth and investor engagement presents opportunities for future success.

Ligand Pharmaceuticals reports robust Q4 earnings and strategic growth moves

Ligand Pharmaceuticals showcased a strong financial performance in Q4 2023, with strategic business streamlining and portfolio enhancements driving growth. Despite supply constraints related to a predecessor product, successful collaborations have ensured manufacturing readiness for key products like Rylaze. The company's diversified portfolio and strong partnerships position it well for continued growth and shareholder returns in 2024.

Ligand Pharmaceuticals reports robust Q1 performance and strategic investments

Ligand Pharmaceuticals shows strong financial performance and growth potential, supported by strategic partnerships and key developments in their portfolio.
While facing challenges like upcoming generic competition and revenue uncertainty from recent deals, the company remains focused on long-term growth.
Opportunities lie in projected revenue and EPS growth, market expansion for Filspari, and continued interest in licensing for revenue diversification.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in Jupiter, FL.

Illumina

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Ligand Pharmaceuticals (LGND) or Illumina (ILMN). But which of these two stocks offers value investors a better bang for their buck right now?

LGND or ILMN: Which Is the Better Value Stock Right Now?

Surmodics

Health Care Select Sector SPDR Fund

After impressive quarterly results on Wednesday, here are two highly-ranked Zacks Medical sector stocks that investors may want to consider.

2 Highly Ranked Medical Stocks to Consider After Healthy Quarterly Results

Ligand Pharmaceuticals (LGND) reports encouraging third-quarter results as earnings and sales beat estimates. Management raises the 2023 financial outlook.

Ligand (LGND) Beats on Q3 Earnings & Sales, Raises '23 View

Ligand Pharmaceuticals Inc. (NASDAQ:LGND ) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Simon Latimer - Head-Investor Relations Todd Davis - Chief Executive Officer Matthew Korenberg - President and Chief Operating Officer Tavo Espinoza - Chief Financial Officer Paul Hadden - Senior Vice President-Investments Conference Call Participants Jack Cole - Craig-Hallum Capital Group Lawrence Solow - CJS Securities Operator Thank you for standing by. My name is Danika and I'll be your conference operator today.

Ligand Pharmaceuticals Inc. (LGND) Q3 2023 Earnings Call Transcript

Although the revenue and EPS for Ligand (LGND) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Compared to Estimates, Ligand (LGND) Q3 Earnings: A Look at Key Metrics

SAN DIEGO--(BUSINESS WIRE)---- $LGND #earnings--Ligand reports third quarter 2023 financial results.

Ligand Reports Third Quarter 2023 Financial Results

In the most recent trading session, Ligand Pharmaceuticals (LGND) closed at $53.30, indicating a +1.93% shift from the previous trading day.

Ligand Pharmaceuticals (LGND) Laps the Stock Market: Here's Why

Ligand (LGND) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ligand Pharmaceuticals (LGND) Earnings Expected to Grow: Should You Buy?

Sanofi

SAN DIEGO--(BUSINESS WIRE)--Ligand Acquires Royalty on Sanofi's TZIELD® for $20 Million.

Ligand Acquires Royalty on Sanofi's TZIELD® for $20 Million

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Ligand Pharmaceuticals (LGND) or Illumina (ILMN). But which of these two companies is the best option for those looking for undervalued stocks?

LGND vs. ILMN: Which Stock Is the Better Value Option?

SAN DIEGO--(BUSINESS WIRE)-- #earnings--Ligand To Report Third Quarter 2023 Financial Results On November 8.

Ligand To Report Third Quarter 2023 Financial Results On November 8

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Why Ligand Pharmaceuticals (LGND) is a Top Value Stock for the Long-Term

In the closing of the recent trading day, Ligand Pharmaceuticals (LGND) stood at $52.09, denoting a -1.31% change from the preceding trading day.

Ligand Pharmaceuticals (LGND) Sees a More Significant Dip Than Broader Market: Some Facts to Know

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Ligand Pharmaceuticals (LGND) or Illumina (ILMN). But which of these two stocks presents investors with the better value opportunity right now?

LGND vs. ILMN: Which Stock Should Value Investors Buy Now?

Ligand (LGND) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Will Ligand (LGND) Beat Estimates Again in Its Next Earnings Report?

Following the acquisition, Ligand (LGND) has full ownership rights to berdazimer gel, all assets related to NITRICIL drug delivery technology platform and rights to the Sitavig program.

Ligand (LGND) Acquires Certain Assets of Novan for $12.2M

SAN DIEGO--(BUSINESS WIRE)--Ligand Acquires Assets of Novan, Inc. for $12.2 Million.

Ligand Acquires Assets of Novan, Inc. for $12.2 Million

SAN DIEGO--(BUSINESS WIRE)--Ligand Appoints Martine Zimmermann to its Board of Directors.

Ligand Appoints Martine Zimmermann to its Board of Directors

Jazz Pharmaceuticals

SAN DIEGO--(BUSINESS WIRE)--Ligand's Partner Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze.

Ligand's Partner Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze® (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

SAN DIEGO--(BUSINESS WIRE)--Ligand's Partner Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI.

Ligand's Partner Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI® Demonstrating Long-Term Kidney Function Preservation in IgA Nephropathy; Narrowly Missing eGFR Total Slope Endpoint versus Active Control

Ligand (LGND) intends to spin out and merge its subsidiary Pelican with Primordial Genetics to form a new standalone company. Post-merger, it will own a 49.9% stake in this new company.

Ligand (LGND) to Spin Out Pelican Subsidiary, Updates '23 View

SAN DIEGO--(BUSINESS WIRE)--Ligand Spins Out and Merges Pelican Subsidiary with Primordial Genetics to Form Primrose Bio.

Ligand Spins Out and Merges Pelican Subsidiary with Primordial Genetics to Form Primrose Bio

SAN DIEGO--(BUSINESS WIRE)--Ligand Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4).

Ligand Pharmaceuticals Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Ligand Pharmaceuticals Incorporated generates revenue through licensing technologies, contractual fees, and the sale of Captisol, a modified cyclodextrin used in drug development. Captisol has been a major source of revenue for Ligand, particularly through its supply deal with Gilead for remdesivir during the COVID-19 pandemic. Ligand has reduced analyst interest and is seeking to acquire and out-license assets from bankrupt companies, indicating a slow-moving and low-profile status.

Ligand: Nothing Exciting Stands Out

Ligand Pharmaceuticals (LGND) reports second-quarter results as earnings beat the estimates, but sales miss the mark. Management raises the 2023 financial outlook.

News for Ligand Pharmaceuticals Stock (LGND)